Articles On Noxopharm (ASX:NOX)

Noxopharm (ASX:NOX) has provided interim data from its NOXCOVID trial that is assessing the company's Veyonda in a cohort of 18 patients with moderately severe COVID- 19 disease.

The Noxopharm Ltd (ASX: NOX) share price has started the week on a positive note. At the time of writing, the clinical-stage drug development company’s shares are up 6% to 67 cents. Why is the Noxopharm share price charging higher? Investo...

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced the lodgement of an international patent application aimed at protecting the use of Veyonda (idronoxil) in blocking the development of septic shock...

Peter Switzer speaks to Graham Kelly, the founder, CEO and managing director of Noxopharm (NOX).

A phase 1b clinical trial testing the safety and efficacy of Noxopharm (ASX:NOX)‘s Veyonda suppository when combined with Bristol Myer Squibb’s immunotherapy drug Opdivo (nivolumab) has received ethics approval. The IONIC-1 trial will immed...

ShareCafeAustralia…One Hour In…ASX200 down 69 points ASX200 down 69 points (1%) to 6676.   Afterpay (-2.8%) / Splitit (-3.2%) / Zip Co (-3.3%); press speculation  that the “RBA will move on the BNPL later sector to force industry players t...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Despite the healthcare leading the gains in the S&P/ASX 200 Index (ASX: XJO) yesterday, there are some healthcare shares that have been out-of-form over the last month. It can sometimes be useful to take a look at which shares are buck...

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced that its lead investigational candidate Veyonda has been approved to move into its second and final stage of the NOXCOVID-1 clinical trial.

The Noxopharm Ltd (ASX: NOX) share price is raced higher on the open this morning. However, the Noxopharm share price has since settled down. The movement comes as a result of the clinical drug developer provided an update on its NOXCOVID...

08 Mar 2021 - Drug development company Noxopharm (ASX:NOX) reports Veyonda has been approved to move into its second and final stage of the NOXCOVID-1 clinical trial.

ShareCafeAustralia…One Hour In…ASX200 up 49 points ASX200 up 49 points (0.7%) to 6838.   Don’t forget the Reserve Bank interest rate decision at 2.30pm.     No change is expected by just about all economists………….   Aristocrat (+0.8%); US F...

A trial of Noxopharm's (ASX: NOX) prostate cancer treatment has delivered a "high response" in men with end-stage cancer, sending the company's stocks up this morning. According to NOX, a trial of the company's LuPIN drug combination has...

ShareCafeNoxopharm Study Finds its Drug Improves Prostate Cancer Survival Rates Noxopharm (ASX:NOX) announced this week independent drug trial results that significantly extended the life of men with prostrate cancer. “Today’s clinical...

At time of writing, the share price of Noxopharm Ltd [ASX:NOX] is up more than 8%, trading at 74 cents. We look at the latest announcement out of the company and the outlook for the NOX share price.... The post Noxopharm Share Price Up on P...

The Noxopharm Ltd (ASX: NOX) share price gained more than 21% today, surging in a last-minute buying frenzy to close at 83 cents. Noxopharm is an Australian clinical-stage drug development company. Its Veyonda drug is being designed to sup...

Noxopharm (ASX:NOX) has announced the publication in an abstract form of the latest survival data from the LuPIN study ahead of a formal presentation to the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposiu...

ShareCafeHidden Gems Webinar Recap – NOX, VMS, EMU, RXL Catch up on the full webinar with presentations from Noxopharrm (ASX:NOX), Venture Minerals (ASX:VMS), EMU Resources (ASX:EMU) & Rox Resources (ASX:RXL) Hidden Gems Webinar Recap...

ShareCafeNoxopharm (ASX:NOX) – Hidden Gems Webinar Presentation     Presenter – Dr. Graham Kelly Founder & CEO  – Noxopharm Limited is a clinical-stage drug development company that focuses on the research and development of drugs to e...

The Noxopharm Ltd (ASX:NOX) share price launched up more than 7% today as the company released its report for the fourth quarter December 2020. At the time of writing, the Noxopharm share price trading up 7.69% at 63 cents. Let’s take a cl...

Noxopharm (ASX:NOX) has announced that the latest formal review by the NOXCOVID-1 Safety Steering Committee has cleared it to advance to the fifth and final dosage cohort.

A trial of medtech Noxopharm's (ASX: NOX) COVID-19 treatment has advanced to the fifth and final stage today, encouraging optimism amongst the company's investors. Shares in the Sydney-based company were up nearly 3 per cent this morning...

A trial of medtech Noxopharm's (ASX: NOX) COVID-19 treatment has advanced to the fifth and final stage today, encouraging optimism amongst the company's investors. Shares in the Sydney-based company were up nearly 3 per cent this morning...

A trial of medtech Noxopharm's (ASX: NOX) COVID-19 treatment has advanced to the fifth and final stage today, encouraging optimism amongst the company's investors. Shares in the Sydney-based company were up nearly 3 per cent this morning...

13 Jan 2021 - Drug development company, Noxopharm (ASX:NOX) reports that the latest formal review by the NOXCOVID-1 Safety Steering Committee has cleared it to advance to the fifth…

Noxopharm CEO Dr Graham Kelly speaks at the Switzer Small and Micro Cap Virtual Investor Day 2020.

While the S&P/ASX 200 Index (ASX: XJO) is slipping today, the Australian clinical-stage drug developer Noxopharm Ltd (ASX: NOX) is bucking the trend with its shares rising. At the time of writing, the Noxopharm share price is up 14.13%...

ShareCafeAustralia…One Hour In…ASX up 52 points ASX200 up 52 points (0.8%) to 6685.   Afterpay (+1.5%); Reserve Bank governor Philip Lowe said the bank was “unlikely” to conclude that Afterpay and other BNPL firms would have to remove thei...

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has completed a $23 million share placement to professional, institutional, and sophisticated investors.

ASX-listed drug developer is Noxopharm has put a $20 million equity raising to investors in an effort to fund studies slated for next year. 

Australian drug development company Noxopharm Limited (ASX: NOX) has announced a major breakthrough this morning on its DARRT cancer therapy drug.  The announcement shot the share price of NOX up by 11% to 63 cents at the opening bell. Wha...

Noxopharm (ASX:NOX) has announced its investigative cancer therapy Veyonda will be trialed with Bristol-Myers Squibb's immunotherapy OPDIVO (nivolumab).

The Noxopharm Ltd (ASX: NOX) share price has started the week in a positive fashion. At one stage today the clinical-stage drug development company’s shares were up as much as 8% to 54 cents. The Noxopharm share price has since pulled back...

05 Nov 2020 - Clinical-stage drug development company Noxopharm Limited (ASX:NOX) has partnered with Hudson Institute of Medical Research and a collaboration with The Australian Na…

Burgeoning medtech company Noxopharm (ASX: NOX) is making strides in the effort race to find a treatment for COVID-19. The Sydney-based clinical-stage drug development company has filled the first two cohorts for its trial of Veyonda, an...

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced that the final patient has completed treatment in the LuPIN study.

Australian biotech, Noxopharm Limited (ASX:NOX) has announced an important milestone with formal approval for immediate initiation of Veyonda®’s clinical trial in COVID-19 patients in Europe. Following the key update, the Company’s...

Clinical-stage drug development player, Noxopharm Limited (ASX:NOX) has recently announced peer-reviewed publication of the LuPIN trial data in the international journal, European Urology Oncology. According to Noxopharm, the publication o...

New important pre-clinical data from two independent laboratories has validated the potential of Noxopharm Limited’s (ASX:NOX) idronoxil (active ingredient in Veyonda®) to restore the cancer-fighting immune function within ‘COLD&rsquo.....

New important pre-clinical data from two independent laboratories has validated the potential of Noxopharm Limited’s (ASX:NOX) idronoxil (active ingredient in Veyonda®) to restore the cancer-fighting immune function within ‘COLD&rsquo.....

The Noxofarm Ltd (ASX: NOX) share price soared after positive results regarding its cancer treatment drug, Veyonda, were released this morning. The immuno-oncology drug development company saw its share price rise 12% to 37 cents on the ne...

Noxopharm Limited (ASX:NOX) is trading ~5 per cent higher (as at 12:01 PM AEST) following the release of its Corporate Presentation for the Reach Markets Virtual Event. Noxopharm is focused on arguably the biggest prize in the pharma indus...

Nyrada (ASX: NYR) has received “encouraging” results from a lab-based cholesterol-lowering study, for the drug it hopes to use to treat hypercholesterolemia — or high cholesterol. The preclinical study used healthy donor human white blood c...

Noxopharm (ASX:NOX) has announced the commencement of its NOXCOVID clinical program with a planned phase one trial in Europe.

Australian clinical stage drug developer, Noxopharm Limited (ASX:NOX) notified in its latest update the commencement of NOXCOVID clinical trial program in Europe, focusing on safety and proof-of principle endpoints of Veyonda® as a potentia...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Clinical t...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Clinical t...

Summary Noxopharm presented two sets of clinical data concerning the development of Veyonda® as a treatment for end-stage prostate cancer at ASCO 2020 Annual Meeting. Highly encouraging interim data from the Phase 1b/2a LuPIN clinical t...

Noxopharm (ASX: NOX) has updated on its presentation of two sets of clinical trial data relating to the development of NOX66 (Veyonda) as a treatment of end-stage cancer.